Identification

Name
Amisulpride
Accession Number
DB06288
Type
Small Molecule
Groups
Approved, Investigational
Description

Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Structure
Thumb
Synonyms
  • 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
  • 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
  • Aminosultopride
  • Amisulprida
  • Amisulpridum
International/Other Brands
Deniban (Sanofi-Aventis) / Solian (Sanofi-Aventis)
Categories
UNII
8110R61I4U
CAS number
71675-85-9
Weight
Average: 369.479
Monoisotopic: 369.172227057
Chemical Formula
C17H27N3O4S
InChI Key
NTJOBXMMWNYJFB-UHFFFAOYSA-N
InChI
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
IUPAC Name
4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide
SMILES
CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC

Pharmacology

Indication

Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 7
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption

Bioavailability is 48% following oral administration.

Volume of distribution
Not Available
Protein binding

Low (17%)

Metabolism
Not Available
Route of elimination
Not Available
Half life

Approximately 12 hours

Clearance
Not Available
Toxicity

Overdoses of amisulpride have been linked with torsades de pointes.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineAmisulpride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAmisulpride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amisulpride.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amisulpride.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amisulpride.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Amisulpride.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amisulpride.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Amisulpride.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amisulpride.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amisulpride.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Amantadine.Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amisulpride.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amisulpride.Experimental
AmphetamineAmisulpride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Amisulpride.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Amisulpride.Vet Approved
AzelastineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Amisulpride.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amisulpride.Approved
BenzphetamineAmisulpride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Amisulpride is combined with Benzyl alcohol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Amisulpride.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Amisulpride.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Amisulpride is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Amisulpride.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amisulpride.Approved, Investigational
BuprenorphineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amisulpride.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amisulpride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Amisulpride.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amisulpride.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amisulpride.Approved, Illicit, Vet Approved
CabergolineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Cabergoline.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Amisulpride.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amisulpride.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amisulpride.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Amisulpride.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amisulpride.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amisulpride.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amisulpride.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amisulpride.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorphenamine.Approved
ChlorphentermineAmisulpride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Amisulpride.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amisulpride.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amisulpride.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amisulpride.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Amisulpride.Approved
ClemastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Amisulpride is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Amisulpride.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amisulpride.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Amisulpride.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amisulpride.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amisulpride.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amisulpride.Approved, Illicit
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Amisulpride.Approved
CyclizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amisulpride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amisulpride.Approved
DesipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amisulpride.Approved
DetomidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amisulpride.Approved, Vet Approved
DextroamphetamineAmisulpride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amisulpride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amisulpride.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amisulpride.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amisulpride.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amisulpride.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Amisulpride is combined with Diethyl ether.Experimental
DiethylpropionAmisulpride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amisulpride.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amisulpride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amisulpride.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amisulpride.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amisulpride.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amisulpride.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Amisulpride.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Amisulpride is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amisulpride.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amisulpride.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amisulpride.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Amisulpride.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Amisulpride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amisulpride.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amisulpride.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amisulpride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amisulpride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amisulpride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amisulpride.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amisulpride.Approved
EthanolAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amisulpride.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amisulpride.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amisulpride.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amisulpride.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amisulpride.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Amisulpride.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amisulpride.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amisulpride.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amisulpride.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amisulpride.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amisulpride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amisulpride.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amisulpride.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amisulpride.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Amisulpride.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amisulpride.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Amisulpride is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amisulpride.Approved, Illicit
GepefrineAmisulpride may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amisulpride.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amisulpride.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amisulpride.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amisulpride.Approved
HydrocodoneAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.Approved, Illicit
HydroxyamphetamineAmisulpride may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amisulpride.Approved
ImipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indiplon.Investigational
Iofetamine I-123Amisulpride may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amisulpride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amisulpride.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amisulpride.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amisulpride.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amisulpride.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amisulpride.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amisulpride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amisulpride.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amisulpride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Amisulpride.Approved, Investigational
LisdexamfetamineAmisulpride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Amisulpride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amisulpride.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amisulpride.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amisulpride.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Amisulpride is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amisulpride.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Amisulpride.Approved
MephedroneAmisulpride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAmisulpride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amisulpride.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Meptazinol.Experimental
MequitazineAmisulpride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amisulpride.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amisulpride.Approved, Illicit
MethamphetamineAmisulpride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amisulpride.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amisulpride.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amisulpride.Approved
MethotrimeprazineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amisulpride.Approved, Vet Approved
MethoxyphenamineAmisulpride may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amisulpride.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amisulpride.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.Approved, Investigational
MetyrosineAmisulpride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.Approved, Illicit
MidomafetamineAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Amisulpride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
MirtazapineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAAmisulpride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amisulpride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amisulpride.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Amisulpride.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amisulpride.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Amisulpride.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amisulpride.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Amisulpride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amisulpride.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amisulpride.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amisulpride.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amisulpride.Approved
OpiumThe risk or severity of adverse effects can be increased when Amisulpride is combined with Opium.Approved, Illicit
OrphenadrineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amisulpride.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amisulpride.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amisulpride.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amisulpride.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amisulpride.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amisulpride.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Amisulpride.Experimental
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.Approved
ParaldehydeAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Amisulpride.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amisulpride.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Amisulpride.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amisulpride.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amisulpride.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amisulpride.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amisulpride.Approved
PhenibutThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amisulpride.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenoxyethanol.Approved
PhentermineAmisulpride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amisulpride.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amisulpride.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amisulpride.Approved
PiribedilThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.Approved
PramipexoleAmisulpride may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amisulpride.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amisulpride.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amisulpride.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Amisulpride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amisulpride.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amisulpride.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Amisulpride is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amisulpride.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Amisulpride.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Amisulpride.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Amisulpride is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Amisulpride is combined with PSD502.Investigational
PseudoephedrineAmisulpride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amisulpride.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amisulpride.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Amisulpride.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Amisulpride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amisulpride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amisulpride.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amisulpride.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amisulpride.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Amisulpride.Investigational
RitobegronAmisulpride may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Amisulpride.Approved
RomifidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Romifidine.Vet Approved
RopiniroleAmisulpride may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride.Approved
RotigotineAmisulpride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amisulpride.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amisulpride.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Amisulpride.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amisulpride.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amisulpride.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amisulpride.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
StiripentolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Amisulpride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Amisulpride.Approved, Investigational
SuvorexantAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Amisulpride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amisulpride.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amisulpride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Amisulpride.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amisulpride.Investigational
ThalidomideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amisulpride.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amisulpride.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Amisulpride.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Amisulpride.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amisulpride.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amisulpride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Amisulpride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amisulpride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amisulpride.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Amisulpride.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amisulpride.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amisulpride.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Amisulpride.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amisulpride.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amisulpride.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amisulpride.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Amisulpride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Amisulpride.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amisulpride.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amisulpride.Approved, Investigational
ZolpidemAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amisulpride.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Amisulpride.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amisulpride.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US4401822
General References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702]
  2. Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. [PubMed:14642970]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800]
  4. Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002 Feb;159(2):180-90. [PubMed:11823257]
  5. Rehni AK, Singh TG, Chand P: Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems. Basic Clin Pharmacol Toxicol. 2011 May;108(5):310-7. doi: 10.1111/j.1742-7843.2010.00655.x. Epub 2010 Dec 22. [PubMed:21176108]
External Links
Human Metabolome Database
HMDB15633
KEGG Drug
D07310
ChemSpider
2074
BindingDB
81790
ChEBI
64045
ChEMBL
CHEMBL243712
Therapeutic Targets Database
DAP000848
PharmGKB
PA162565877
IUPHAR
963
Guide to Pharmacology
GtP Drug Page
Wikipedia
Amisulpride
ATC Codes
N05AL05 — Amisulpride
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
1CompletedTreatmentSchizophrenic Disorders1
1RecruitingTreatmentSchizophrenic Disorders1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentSchizophrenic Disorders1
3CompletedTreatmentClozapine-induced Hypersalivation1
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedTreatmentNeurocognitive Function / Tardive Dyskinesia1
4CompletedTreatmentPsychosis / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders7
4RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4RecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4TerminatedTreatmentSchizophrenic Disorders2
4Unknown StatusBasic ScienceSchizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedNot AvailableAddictions1
Not AvailableCompletedNot AvailableNormal Volunteers1
Not AvailableCompletedBasic ScienceDiabetes / Insulin Resistance / Schizophrenic Disorders1
Not AvailableCompletedDiagnosticSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentMetabolic Syndromes1
Not AvailableNot Yet RecruitingTreatmentSchizophrenic Disorders1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingBasic ScienceHistory of Childhood Sexual Abuse (CSA) / Major Depressive Disorder (MDD)1
Not AvailableWithdrawnTreatmentSchizophrenic Disorders / Treatment Resistant Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)181-182 °CPhysProp
logP1.06MANNHOLD,R ET AL. (1990)
pKa9.37Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.293 mg/mLALOGPS
logP1.5ALOGPS
logP0.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)7.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity99.84 m3·mol-1ChemAxon
Polarizability39.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.864
Blood Brain Barrier+0.9441
Caco-2 permeable-0.7127
P-glycoprotein substrateSubstrate0.7242
P-glycoprotein inhibitor INon-inhibitor0.8209
P-glycoprotein inhibitor IINon-inhibitor0.8668
Renal organic cation transporterNon-inhibitor0.7899
CYP450 2C9 substrateNon-substrate0.794
CYP450 2D6 substrateNon-substrate0.8272
CYP450 3A4 substrateSubstrate0.5667
CYP450 1A2 substrateNon-inhibitor0.8888
CYP450 2C9 inhibitorNon-inhibitor0.8348
CYP450 2D6 inhibitorNon-inhibitor0.8572
CYP450 2C19 inhibitorNon-inhibitor0.8578
CYP450 3A4 inhibitorNon-inhibitor0.8942
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9081
Ames testNon AMES toxic0.5931
CarcinogenicityNon-carcinogens0.6637
BiodegradationNot ready biodegradable0.8868
Rat acute toxicity2.4706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9398
hERG inhibition (predictor II)Inhibitor0.7128
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0609000000-2b372299b7870a4920eb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-99c1cc37ab9cf4683323
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0409000000-4e053b8ec1d55ced8499
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004l-0974000000-de9354d79437a4df60bc
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01q9-0900000000-f91d53fb9c883bae9ca3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-324b93e2df83509f8048
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-99ab45809f8e56fbb616
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014l-0109000000-93205a0e84bbb061506a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-057i-0960000000-23d53c22f66a40ded55b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0509000000-de0803e7c69539424a4e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0019000000-7dec57b5001ab24504cc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0019000000-c532dacf370f0075220b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0092000000-6deb7fed54b4631e9813
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0005-0980000000-c78d2a361bbc674b41ce
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0005-0960000000-6a4706ff5588c4035137
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0190000000-e410c0158058e8740df0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0009000000-2237ffbc12b8e6459da5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0029000000-2143af7abc829fd8cacd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0290000000-bb210e691e1906ae74a7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0590000000-5f6a35609afc11e248ef
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0920000000-b89e4616edb7a54d2976
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-1900000000-15fd75a1097964a2b372
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0009000000-34c03de48e9e080e3c47
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0029000000-35268399499c0c04d5f5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0290000000-ad61214eeef71e97665b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0590000000-8322cbf2d5910eb0bd03
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0920000000-cbc60b473b3fb0de43ab
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-1900000000-c32487a90cfd10db9961
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0190000000-458205e2fa61496c6a54
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dl-2689000000-c4a31e81f70bf838ae8f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dl-0269000000-e2c8021fa5c019a7a29e

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzamides. These are organic compounds containing a benzamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzamides
Alternative Parents
Aminophenyl ethers / Methoxyanilines / Benzenesulfonyl compounds / Benzamides / Phenoxy compounds / Methoxybenzenes / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / N-alkylpyrrolidines
show 9 more
Substituents
Aminobenzamide / Methoxyaniline / Benzamide / Aminophenyl ether / Benzenesulfonyl group / Phenol ether / Aniline or substituted anilines / Methoxybenzene / Benzoyl / Phenoxy compound
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfone, benzamides, pyrrolidines, aromatic amine, aromatic amide (CHEBI:64045)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702]
  2. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702]
  2. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL: Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009 Jul;205(1):119-28. doi: 10.1007/s00213-009-1521-8. Epub 2009 Apr 1. [PubMed:19337725]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Tyson PJ, Roberts KH, Mortimer AM: Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004 Jun;114(6):593-611. [PubMed:15204055]

Drug created on March 19, 2008 10:22 / Updated on October 02, 2017 05:44